Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  ArGEN-X    ARGX   NL0010832176

ARGEN-X (ARGX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

arGEN X : argenx to Present at Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2018 | 07:01am CEST

May 17, 2018

Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that Chief Executive Officer, Tim Van Hauwermeiren, will present at several upcoming investor conferences:

  • UBS 2018 Global Healthcare ConferenceCompany presentation on Tuesday, May 22, 2018 at 2:00 p.m. ET in New York City.
  • Jefferies 2018 Global Healthcare Conference. Company presentation on Wednesday, June 6, 2018 at 1:30 p.m. ET in New York City.
  • JMP Securities Life Sciences ConferencePanel discussion on Wednesday, June 20, 2018 at 10:30 a.m. ET in New York City.

Live webcasts of the UBS and Jefferies presentations will be available on the Company's website at www.argenx.com. Replays of the webcasts will be available for 90 days following the presentation.

About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  

www.argenx.com

For further information, please contact:

Joke Comijn, Corporate Communications & IR Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx's expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: argenx SE via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARGEN-X
09/21ARGEN X : argenx announces closing of U.S. public offering
PU
09/21ARGEN X : argenx announces closing of U.S. public offering for gross proceeds of..
GL
09/19ARGEN X : argenx announces launch of proposed public offering in the United Stat..
AQ
09/19ARGEN X : argenx reports positive topline results from Phase 2 proof-of-concept ..
AQ
09/19ARGEN X : argenx raises approximately $300.6 million in gross proceeds in a U.S...
GL
09/17ARGEN X : argenx announces launch of proposed public offering in the United Stat..
GL
09/17ARGEN X : argenx trumpets topline results from drug tests
AQ
09/17ARGEN X : argenx reports positive topline results from Phase 2 proof-of-concept ..
GL
09/10ARGEN X : argenx doses first patient in global Phase 3 registration trial of efg..
AQ
09/06ARGEN X : argenx doses first patient in global Phase 3 registration trial of efg..
PU
More news
News from SeekingAlpha
09/21YOUR DAILY SCOOP : Unum's Positive Data, Theravance's Treatment Benefit, Collect.. 
09/20Sell-siders defend Argenx after selloff; shares up 5% premarket 
09/20Premarket analyst action - healthcare 
09/19Argenx prices $300M equity offering 
09/18Argenx (ARGX) Updates Efgartigimod ITP Ph2 Topline Data - Slideshow 
Financials (€)
Sales 2018 36,8 M
EBIT 2018 -65,2 M
Net income 2018 -50,8 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 65,5x
Capi. / Sales 2019 59,9x
Capitalization 2 409 M
Chart ARGEN-X
Duration : Period :
arGEN-X Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGEN-X
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 120 €
Spread / Average Target 79%
EPS Revisions
Managers
NameTitle
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Peter K. M. Verhaeghe Chairman
R. Keith Woods Chief Operating Officer
Eric Castaldi CFO & Principal Accounting Officer
Hans J. W. de Haard Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARGEN-X24.90%2 611
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.17%46 021
REGENERON PHARMACEUTICALS3.81%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170